MAINZ, Germany, and SHANGHAI, China, March 16, 2020 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun Pharma” or “Group”; Stock Symbol: 600196.SH, 02196.HK) announced today a strategic development and commercialization collaboration to advance BioNTech’s mRNA vaccine candidate BNT162 in China for the prevention of COVID-19 infections.

Under the terms of the agreement, the two companies will work jointly on the development of BNT162 in China. The companies will collaborate to conduct clinical trials in China leveraging Fosun Pharma’s extensive clinical development, regulatory, and commercial capabilities in the country.

If approved, Fosun Pharma will commercialize the vaccine in China. BioNTech will supply the mRNA vaccine for clinical trials from GMP manufacturing facilities in Europe along with its partner Polymun. BioNTech will retain full rights to develop and commercialize the vaccine in the rest of the world.

“The first issue is living space…

Anybody who has been to Western countries knows that their living space is much better than ours….

But the term ‘living space’ (lebensraum) is too closely related to Nazi Germany. The reason we don’t want to discuss this too openly is to avoid the West’s association of us with Nazi Germany, which could in turn reinforce the view that China is a threat. Therefore, in our emphasis on He Xin’s new theory, “Human rights are just living rights,” we only talk about “living,” but not “space,” so as to avoid using the term “living space…

Only countries like the UNITED STATES, CANADA and AUSTRALIA have the vast land to serve OUR NEED FOR MASS COLONIZATION.” ~ Chinese Communist Party General Chi Haotian Continue reading →